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Summary 
In this study we have investigated the effects ofinterleukin 10 (IL-10) on human peripheral blood 
eosinophils stimulated with granuloyte/macrophage colony stimulating factor (GM-CSF)  and 
lipopolysaccharide (LPS). We show that LPS was able to enhance eosinophil survival in a dose- 
dependent manner, as well as release of the cytokines GM-CSF,  tumor necrosis factor or, and 
IL-8. LPS-induced eosinophil survival was largely inhibited by an anti-GM-CSF  neutralizing 
antibody and completely blocked by polymyxin B, suggesting GM-CSF involvement in the survival 
enhancing mechanism and LPS specificity, respectively. IL-10 significantly inhibited survival of, 
and cytokine production from, eosinophils induced by LPS, but did not inhibit the survival induced 
by GM-CSF. These observations suggest a novel activation mechanism of eosinophils and, also, 
that IL-IO may participate in the regulation of diseases characterized by eosinophil infiltration. 
H 
uman eosinophils, like other granulocytes, are terminally 
differentiated defense effector cells that are recruited from 
the  bloodstream  into  tissue  sites  during  inflammatory, 
particularly allergic, reactions (1, 2). Recent evidence from 
us (3, 4) and others (5-10) indicates that in addition to their 
capacity to release lipid mediators (11) and granule proteins 
(12), eosinophils may contribute to the inflammatory process 
through  expression  and  synthesis  of cytokines  including 
TGF-oJ[3, TNF-oe, MIP-lc~, IL-1, IL-5, IL-8, GM-CSF, and 
IL-6. While stimuli such as calcium ionophore and ionomycin 
have been found capable of eliciting cytokine expression in 
eosinophils in vitro (9,  13,  14),  which physiologic stimuli, 
and  which  underlying  mechanisms  are  involved  in  the 
regulation of eoslnophil cytokine responses still remain largely 
unknown. 
IL-10 is a recently identified cytokine primarily produced 
by mononuclear cells  (15),  with  potent  antiinflammatory 
activities. This molecule has been shown to inhibit the release 
of cytokines from monocytes (16),  T  lymphocytes (17) and 
neutrophils  (18),  but  its  effect  on  effector  activities  of 
eosinophils remains to be elucidated. 
In  this  report,  we  demonstrate  that  IL-10  is  a  potent 
inhibitor of both  eosinophil survival and secretion of the 
proinflammatory  cytokines  GM-CSF,  TNF-ot,  and  IL-8 
induced by an infectious agent, LPS, thus providing potential 
novel mechanisms for activation and regulation of functions 
of human eosinophils. 
Materials and Methods 
Reagents.  Recombinant human (rh) GM-CSF (1 U  =  40 pg) 
was kindly provided by Dr. John Abrams (DNAX Research Insti- 
tute, Palo Alto, CA). Recombinant human Ib10 was purchased 
from Pepro Tech Inc. (Rocky Hill, NJ). LPS (from 055:B5 Eschericia 
colO, polymyxin B, and mouse IgGl were purchased from Sigma 
Chemical Co. (St. Louis, MO). The specific mouse anti-human 
GM-CSF monodonal antibody was purchased from Genzyme Corp. 
(Cambridge,  MA). 
Isolation and Culture of Human Eosinophils.  Blood was drawn 
from healthy nonatopic volunteers (skin test negative). Eosinophils 
were isolated by negative-immunomagnetic selection using an an- 
tibody against CD16, a FcRIII receptor found on neutrophils but 
not eosinophils (19). Briefly, red blood cells were removed from 
100 ml of the whole blood by dextran (clinical grade; ICN Bio- 
medicals Inc., Costa Mesa, CA) sedimentation. A granulocyte layer 
was obtained by density centrifugation on a Percoll gradient (1.079; 
1.100, prepared in HBSS) and was resuspended in Ca  2+ free HBSS. 
The residual contaminating erythrocytes were eliminated by hypo- 
tonic lysis. Granulocytes were resuspended in 2% FCS in HBSS 
and incubated for 40 rain at 4~  with anti-CD16 conjugated with 
micromagnetic beads (Miltenyi Biotec GmbH, Bergisch-Gladbach, 
Germany). Upon passing through the magnetic column (MACS: 
Miltenyi Biotec GmbH), neutrophils bound to the beads were re- 
tained within the column, whereas eosinophils were eluted out 
and collected. This purification procedure resulted in a highly pure 
eosinophil population (>99%). Eosinophils were cultured in RPMI 
medium supplemented with 10% FCS, 100 U/ml penicillin and 
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or specific inhibitors. 
Eosinophiil  Survival.  Eosinophils  were cultured in 96-well  plates 
(2  x  10S/well  in 0.2 ml medium). Cells were removed from each 
well after gentle pipetting and viability was assessed  at days 2 and 
4 by Trypan blue exclusion using a hemocytometer. 
Cytokine Assays,  Eosinophils  were cultured in the presence of 
LPS with or without IL-10 in 24-well plates and supernatants col- 
lected at 24 h  (2  x  10S/well in 0.5  ml of medium).  GM-CSF, 
TNF-c~, and Ib8 contents in supematants were measured  by ELISA 
(Amersham International,  Little Chalfort,  UK). The sensitivity 
of these assays  was 1.5 pg/ml, 4.4 pg/ml, and 4.7 pg/ml for GM- 
CSF, TNF-c~, and IL-8, respectively. 
Data Analysis.  Data were expressed as mean  +_ SEM. Wher- 
ever applied, the significance  of differences  in results was analyzed 
by analysis  of variance. The differences  were considered statistically 
significant when iv <0.05. 
Results and Discussion 
Effect of lL-lO on Eosinophil Survival Induced by GM-CSE 
We and others have previously shown that GM-CSF promotes 
the survival of human peripheral blood eosinophils (20, 21). 
To investigate whether IL-10 modulated this effect, human 
peripheral blood eosinophils were incubated with different 
amounts of rhGM-CSF in the presence ofrhlL-10 (5 or 20 
ng/ml), and viability assessed at day 4. Consistent with our 
previous findings (20),  the viability of eosinophils cultured 
in R.PMI  alone was <20%  at day 4, whereas GM-CSF en- 
hanced survival in a dose-dependent manner with maximal 
stimulation observed at 1 U/ml (88  +_ 2.4%) (Fig.  1). Coin- 
cubation with either 5 or 20 ng/ml of IL-10  had no effect 
on eosinophil survival (Fig.  1). Similar results were observed 
when eosinophils were pretreated with IL-10 for 4 h before 
exposure to GM-CSF  (data not shown). 
Effect of LPS on Eosinophil Survival.  LPS is a major com- 
ponent of the outer membrane of Gram negative bacteria and 
it has been shown to induce many ceUular responses including 
survival and cytokine production by monocyte/macrophages, 
neutrophils and some tissue stromal cells  (22-24).  To our 
knowledge, the only evidence of  LPS stimulation of  eosinophils 
is the work by Pozo et al. (7) showing IL-1 release from LPS- 
stimulated peritoneal eosinophils from parasite infected mice. 
The a priori criterium used to determine responsiveness to 
LPS was as follows: when day 4 survival of eosinophils ex- 
posed to LPS was within the range of mean  _+  2 SD of day 
4 survival of untreated (control) eosinophils, we considered 
this "nortresponsiveness."  Interestingly, we found that respon- 
siveness to LPS of  eosinophil preparations from healthy donors 
followed a rather bimodal pattern.  Indeed, close to 40% of 
preparations showed a day 4 survival of 13.6  _+ 9.6% (mean 
+_ SD). In contrast, over 60% of preparations showed a day 
4 survival of 72.7  _+  14.5%  (mean  _+  SD). The reasons for 
this distinct response are not immediately dear, and samples 
from the nonresponder group were excluded from further 
experimentation. In the remaining samples,  LPS markedly 
enhanced eosinophil survival in a dose-dependent fashion, with 
maximal stimulation seen with as low as 0.1 ng/ml of LPS 
(Fig. 2). To demonstrate the spedficity of LPS action on eo- 
sinophil survival, LPS (10 ng/ml) was preincubated with a 
specific LPS inhibitor, polymyxin B (50 U/ml), that has been 
shown to form a stable  complex with the lipid A  moiety 
of LPS (25).  As shown in Fig. 3,  pretreatment of the LPS 
sample with polymyxin B entirely abolished the LPS-induced 
eosinophil survival (66.5  +_  2.8%  by LPS vs. 6.6  +_  2.9% 
by LPS pretreated with polymyxin B), To rule out the possi- 
bility that polymyxin B had a direct effect on eosinophil sur- 
vival, we exposed untreated and GM-CSF (1 U/ml)-treated 
eosinophils to polymyxin B (50  U/ml) and examined sur- 
vival at day 4.  Survival  of untreated eosinophils with and 
without polymyxin B was 3.0 and 3.4%, respectively. Sur- 
vival of GM-CSF-treated eosinophils with and without poly- 
myxin B was 88.0 and 89.3%,  respectively (n  =  2).  Thus, 
polymyxin B had little, if any, effect on eosinophil survival 
of itself.  Together, these data indicate the specificity of LPS 
action on eosinophils.  The molecular mechanisms underlying 
LPS-eosinophil interaction remain speculative  at this time. 
Both CD14 and CDllb/CD18 have been shown or proposed 
to be receptors for LPS on monocyte/macrophages and neu- 
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Figure  1.  Effect of rhIL-10 on eosinophil  survival induced by rhGM- 
CSF. Freshly isolated eosinophils (2  x  10  s) were cultured  in the presence 
of increasing concentrations  of GM-CSF with or without rhlL-10. Sur- 
viwl was assessed at day 4 by Trypan blue dye exclusion. Results  are ex- 
pressed as mean  _+  SEM from five independent  experiments. 
Figure  2.  Effect of LPS on eosinophil  survival.  Freshly  isolated  eo- 
sinophils (2  x  10  s) were cultured with increasing concentrations  of LPS 
and eosinophil survival was assessed at day 4 by Trypan blue dye exclusion. 
Results  represent  mean  +  SEM from three  independent  experiments. 
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induced  eosinophil  survival  by 
polymyxin  B. Freshly isolated en- 
sinophils (2 x  10  s) were cultured 
with LPS which had been pre- 
incubated with polymyxin B (50 
U/m1) for 1 h at 37~  Survival 
was assessed at day 4 by Trypan 
blue dye exclusion. Results are ex- 
pressed as  mean  •  SEM  from 
three  independent experiments. 
(Asterisle) statistically significant 
difference  compared  with  LPS 
alone (p <0.01). 
trophils (22, 26, 27). Our data by immunocytochemistry  sug- 
gest that eosinophils do not possess CD14 molecules on their 
surface (data not shown). However, expression of CDllb/ 
CD18 by eosinophils (28) suggests the presence of potential 
LPS-binding  sites on these cells. 
Effect of  lL-lO on EosinoFhil Survival Induced by LP$.  Fig. 
4 shows that exposure of eosinophils to rhlL-10 significantly 
suppressed LPS-induced eosinophil survival in a dose-depen- 
dent fashion at days 2 and 4 of culture.  The minimum in- 
hibitory concentration of IL-10 appeared to be 0.2 ng/ml and 
complete inhibition was observed with 5 ng/ml of  IL-10 (12.8 
_+ 4.6% at day 4). The observation that IL-10 inhibited eo- 
sinophil survival induced by LPS but not GM-CSF implies 
different mechanisms underlying enhancement of eosinophil 
survival by these two signals. 
We  and  others  have  previously  shown  that  glucocor- 
ticosteroids prevent eosinophil survival induced by GM-CSF 
(29, 30). It was therefore appropriate to investigate whether 
glucorticosteroids would also inhibit LPS-induced eosinophil 
survival. To this end, eosinophil cultures were treated with 
budesonide  (10 .6 M),  a potent synthetic steroid,  and ex- 
posed 1 h later to LPS (10 ng/ml). We found that budesonide, 
similar to IL-10, markedly prevented also LPS-induced sur- 
vival enhancement, 21  +  2.9% at day 2 and 4.2  +  1.4 at 
day4(n  =  3). 
Effect of lL-10 on Eosinophil Cytokine Secretion Induced by 
LPS.  Having established the inhibitory effect of IL-IO on 
LPS-induced eosinophil survival, we proceeded to examine 
whether LPS could stimulate eosinophils to release  proinflam- 
matory cytokines and the modulatory effect oflL-10 in these 
responses. Eosinophils stimulated by 10 ng/ml of LPS were 
cultured with or without 5 ng/ml of IL-10 for 24 h and the 
resulting supernatants were assayed  by ELISA for GM-CSF, 
TNF-c~, and IL-8. Table I shows that unstimulated eosinophils 
did not release detectable levels of  GM-CSF and released only 
very low levels of TNF-c~ and IL-8. LPS challenge resulted 
in a '~ 10-20-fold increase in cytokine release (23.0  +  8.4, 
44.2  _+  14.4, and 2037  +_ 1214 pg/ml ofGM-CSF, TNF-oh 
and IL-8, respectively). Coincubation with IL-10 markedly 
inhibited LPS-induced secretion of these three cytokines by 
eosinophils. 
Since the eosinophil preparations that we used were highly 
purified (>99%), the possibility that these increased amounts 
of cytokines were contributed by other cell types such as 
mononudear cells and neutrophils,  seemed very unlikely. To 
completely  rule out this option, separate cultures containing 
the maximum number of potentially contaminating mono- 
nuclear cells or neutrophils (10,000/ml) were stimulated with 
10 ng/ml of LPS for 24 h and the resulting supernatants as- 
sayed  for GM-CSF by ELISA. Only minimal amounts of  GM- 
CSF  were detected in  supernatants  from LPS-stimulated 
mononuclear cells (1.4 _+ 0.7 pg/ml; n  =  5) or neutrophils 
(1.5  +  1.2 pg/ml; n  =  5) indicating that the contribution 
from these cell populations to cytokine content in the eosin- 
ophil supernatants was indeed negligible. Together these data 
demonstrate that human peripheral blood eosinophils can be 
activated to release substantial amounts of cytokines directly 
by LPS. 
Modulation of LPS-induced Survival by Anti-GM-CSF Anti- 
bodies.  The finding that both rhGM-CSF and LPS enhance 
eosinophil survival and that LPS stimulates these ceils to re- 
lease GM-CSF, led us to hypothesize that LPS-induced eo- 
sinophil survival was secondary to the induction of  GM-CSF 
in eosinophils by LPS. To address this issue, eosinophils were 
cultured in the presence of LPS with 0.4 #g/ml of a mouse 
Table  1.  Cytoleine Release  by Eosinophils 
GM-CSF  TNF-c~  IL-8 
Figure 4.  Effect  of rhIL-10  on eosinophil  survival  induced by LPS. Freshly 
isolated eosinophils (2  x  10  s) were cultured with LPS in the presence 
of different concentrations  of IL-10. Survival was assessed at days 2 and 
4 by Trypan blue dye exclusion. Results represent mean  •  SEM from 
six independent experiments. (Asterisk) statistically significant difference 
compared with LPS alone (p <0.001). 
Control  0  5.7  +  1.7  277  +  119 
LPS  23.0  _+  8.4  44.2  +_  14.4  2,037  +_  1,214 
IL-IO  +  LPS  0.9  +  0.4  6.3  _+  5.0  251  +_ 93 
Freshly isolated eosinophils (5  x  10  s) were cultured for 24 h with or 
without IL-10 (5 ng/ml) in the presence of LPS (10 ng/ml). Results 
represent  means  +  SEM from three  independent experiments. 
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induced eosinophil survival by 
anti-GM-CSE Freshly  isohted  en- 
sinophils (2 ￿  10  s) were  cultured 
with LPS in the presence of 0.4 
/~g/ml mouse anti-human GM- 
CSF or 0.4/~g/ml mouse IgGl. 
Survival was assessed  at day 4 by 
Trypan  blue  dye exclusion.  1~ults 
are expressed as mean +  SEM 
from three independent experi- 
ments. (Asterisk) statistically  fig- 
nificant  difference  compared  with 
LPS alone (p <0.01). 
monoclonal  neutralizing  antibody specifically against human 
GM-CSF, or with the same concentration of normal mouse 
IgGt as a control, and survival  was assessed at day 4.  As 
shown in Fig. 5, the presence of anti GM-CSF but not IgG1 
markedly blocked LPS-induced eosinophil survival (19.9  _+ 
0.3%). This indicates that LPS increases eosinophil survival, 
at least in a substantial part, through stimulation  of GM- 
CSF release from eosinophils thus suggesting an interesting 
mechanism of self-activation.  Moreover, it further supports 
the notion that IL-10 suppresses LPS-induced eosinophil sur- 
vival through blockade of LPS-induced GM-CSF production. 
Our data provide evidence that IL-10 inhibits effector ac- 
tivities of  eosinophils in vitro. This, together with other pub- 
lished evidence on monocytes (16), neutrophils (18), and lym- 
phocytes (17) suggests that IL-10 is a potent antiinflammatory 
cytokine. The inhibitory effect of IL-10 on eosinophils ap- 
pears to be selective since it only inhibits LPS-induced sur- 
vival and cytokine production but not GM-CSF--mediated 
survival. While the molecular mechanisms underlying LPS 
stimulation and suppressive action by IL-10 on cytokine re- 
sponses  in eosinophils remain  to be  fully elucidated, our 
findings suggest a regulatory role for IL-10 in inflammatory 
diseases characterized by eosinophilic infiltration. 
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